Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125420951 | 12542095 | 1 | I | 20160330 | 20160412 | 20160708 | 20160708 | EXP | US-SEATTLE GENETICS-2016SGN00528 | SEATTLE GENETICS | 0.00 | Y | 0.00000 | 20160708 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125420951 | 12542095 | 1 | PS | brentuximab vedotin | BRENTUXIMAB VEDOTIN | 1 | Intravenous (not otherwise specified) | 1.2 MG/KG, Q14D | 1 | MG/KG | U | 125388 | 1.2 | MG/KG | INJECTION | ||||
| 125420951 | 12542095 | 2 | SS | brentuximab vedotin | BRENTUXIMAB VEDOTIN | 1 | 1 | MG/KG | U | 125388 | INJECTION | ||||||||
| 125420951 | 12542095 | 3 | SS | DOXORUBICIN HYDROCHLORIDE. | DOXORUBICIN HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | 25 MG/M2, Q14D | 25 | MG/M2 | U | 0 | 25 | MG/M**2 | |||||
| 125420951 | 12542095 | 4 | SS | DOXORUBICIN HYDROCHLORIDE. | DOXORUBICIN HYDROCHLORIDE | 1 | 25 | MG/M2 | U | 0 | |||||||||
| 125420951 | 12542095 | 5 | SS | Vinblastine | VINBLASTINE | 1 | Intravenous (not otherwise specified) | 6 MG/M2, Q14D | 6 | MG/M2 | U | 0 | 6 | MG/M**2 | |||||
| 125420951 | 12542095 | 6 | SS | Vinblastine | VINBLASTINE | 1 | 6 | MG/M2 | U | 0 | |||||||||
| 125420951 | 12542095 | 7 | SS | DACARBAZINE. | DACARBAZINE | 1 | Intravenous (not otherwise specified) | 375 MG/M2, Q14D | 375 | MG/M2 | U | 0 | 375 | MG/M**2 | |||||
| 125420951 | 12542095 | 8 | SS | DACARBAZINE. | DACARBAZINE | 1 | 375 | MG/M2 | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125420951 | 12542095 | 1 | Hodgkin's disease |
| 125420951 | 12542095 | 2 | Lymphoma AIDS related |
| 125420951 | 12542095 | 3 | Hodgkin's disease |
| 125420951 | 12542095 | 4 | Lymphoma AIDS related |
| 125420951 | 12542095 | 5 | Hodgkin's disease |
| 125420951 | 12542095 | 6 | Lymphoma AIDS related |
| 125420951 | 12542095 | 7 | Hodgkin's disease |
| 125420951 | 12542095 | 8 | Lymphoma AIDS related |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125420951 | 12542095 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125420951 | 12542095 | Febrile neutropenia | |
| 125420951 | 12542095 | Hypokalaemia | |
| 125420951 | 12542095 | Hyponatraemia | |
| 125420951 | 12542095 | Soft tissue infection |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125420951 | 12542095 | 1 | 20160330 | 20160330 | 0 | |
| 125420951 | 12542095 | 3 | 20160330 | 20160330 | 0 | |
| 125420951 | 12542095 | 5 | 20160330 | 20160330 | 0 | |
| 125420951 | 12542095 | 7 | 20160330 | 20160330 | 0 |